Latest News
10.12.2025
Anaveon announces poster presentation at the 2025 European Society for Medical Oncology – Immuno-Oncology (ESMO-IO) Congress
— Anaveon will present further progress in EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors — Basel, December 10, 2025 – Anaveon, a global clinical stage, immuno-oncology company, will present a…Read more
27.10.2025
Anaveon announces poster presentation at the 2025 American College of Rheumatology Convergence
— Anaveon will present ANV200, a novel, highly potent Fc-engineered anti-PD-1 agonistic antibody designed to deplete pathogenic T cells expressing high to low levels of PD-1 — Basel, October 27, 2025 – Anaveon, a global clinical stage, immunology company, will present a poster on ANV200 at…Read more
19.10.2025
Anaveon announces poster presentation at the 2025 European Society for Medical Oncology Annual Meeting
— Anaveon will present progress in EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors — Basel, October 19, 2025 – Anaveon, a global clinical stage, immuno-oncology company, will present a…Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com